Company

Thomson Medical Group Limited

SGX:A50

Operator of private hospitals and clinics, with the group's distinctive concentration in women's health, fertility and maternity care. Its Singapore assets include Thomson Medical Centre and a network of women's clinics, fertility/IVF services and paediatric centres; it also operates in Malaysia (Thomson Hospital Kota Damansara) and Vietnam (FV Hospital, acquired 2023). The longevity-relevant limb is reproductive ageing: IVF and fertility treatment address declining ovarian reserve and age-related fertility loss in an ageing, low-birth-rate region. This is clinical service delivery, not geroscience research; the group does not develop ageing-directed therapeutics or biomarkers. Inclusion is on listing and HQ grounds (SGX-listed, Singapore-headquartered), with fertility as the thematic tie rather than any lifespan or healthspan intervention.

At a glance

Listing
SGX:A50
Category
Healthtech
Headquarters
Singapore
Market cap
Not disclosed

Thesis

Why it is in this universe

Category
Healthtech
Market
Singapore
Recent inflection
Board and financial reset in early 2026: Tong Kooi Ong was appointed Independent Non-Executive Chairman effective 1 February 2026, succeeding Ng Ser Miang, in a move linked to the group's capital-intensive Johor Bay development in the Johor-Singapore Special Economic Zone. H1 2026 revenue rose to S$215.9m from S$201.9m a year earlier, with the net loss narrowing to S$10.2m, following an FY2025 loss driven by interest expense on the FV Hospital (Vietnam) acquisition and weaker Malaysian performance. (Reported via Simply Wall St; not independently confirmed against the SGX filing.)
Services
None recorded
People tracked
2

Market data

Listing and scale

MetricDetail
ExchangeSGX
TickerSGX:A50
Secondary listingNone
Market capNot disclosed
StatusListed and trading
Editor's noteA listing or financing event is not a clinical result. variis grades evidence on the linked protocol, not the share price.

Get in touch

Contact

Address
Singapore
Phone
No public number published
Email
No public address published

Offering

What it sells today

No commercial services are recorded for this company yet.

Recent inflection

What moved lately

Board and financial reset in early 2026: Tong Kooi Ong was appointed Independent Non-Executive Chairman effective 1 February 2026, succeeding Ng Ser Miang, in a move linked to the group's capital-intensive Johor Bay development in the Johor-Singapore Special Economic Zone. H1 2026 revenue rose to S$215.9m from S$201.9m a year earlier, with the net loss narrowing to S$10.2m, following an FY2025 loss driven by interest expense on the FV Hospital (Vietnam) acquisition and weaker Malaysian performance. (Reported via Simply Wall St; not independently confirmed against the SGX filing.)

Keep reading

Related coverage from the newsroom.

Suggest an updateJoin the community

Every entity profile on variis is sourced. Not investment advice.